Overview

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Status:
Withdrawn
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Treatments:
Cemiplimab